Physician profile
Subhash Chandra
NPI 1174817720
$2,929.76
in general payments reported to CMS, 2019-2025
19 companies · $70.55 in 2025
The $70.55 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,537 · 2020: $186 · 2021: $224 · 2022: $115 · 2023: $604 · 2024: $193 · 2025: $70.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467 · Travel and Lodging: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.06 |
| Travel and Lodging | $399.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $1,198.91 | 2019 | |
| Abbvie INC. | $443.60 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Ovesco Endoscopy USA, INC. | $399.86 | 2023 | |
| Medtronic, INC. | $197.13 | 2022-2024 | Manoscan, Gi Genius, Endoflip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.96 | 2019-2021 | |
| Gilead Sciences, INC. | $138.49 | 2019-2020 | |
| Ethicon US, LLC | $125.00 | 2019 | |
| Ardelyx, INC. | $32.63 | 2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $30.67 | 2021 | |
| Qol Medical, LLC | $30.50 | 2021 | |
| Eton Pharmaceuticals, INC. | $29.98 | 2025 | Galzin, Carglumic Acid, Nitisinone |
| Celgene Corporation | $29.28 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $24.48 | 2024 | Dupixent |
| Janssen Biotech, INC. | $24.42 | 2019-2021 | |
| Amgen INC. | $23.19 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $22.91 | 2021 | |
| Alfasigma USA, INC. | $17.87 | 2020 | |
| Pfizer INC. | $12.34 | 2020 | |
| Endogastric Solutions, INC | $9.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.